Hey DD, have you ever spoken to the difficulty of unseating a very entrenched incumbent (AGN/Botox) with respect to RVNC. I wonder what your thoughts are. I realize that there are a few differences with RT002, as this is a product not paid for by insurance, but can AGN employ tactics that slow RT002 uptake (ala ABBV/Humira and others)? Or are those games enabled by our convoluted drug payment system?
RVNC's valuation seems completely mis-aligned if they can take even moderate market share from Botox.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.